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Abstract
We report the useof a novel algorithm that can increase speciﬁcity, and potentially sensitivity, of a screening test.
We used this new algorithm to detect more autoantibodies to p53 in sera of patients with ovarian cancer than
when we use a traditional multiplex approach, by combining p53 protein and selected conﬁrmatory epitopes.
Background: Measurement of autoantibodies (AAbs) to tumor-associated antigens has been proposed to aid in the
early detection of ovarian cancer with high speciﬁcity. Here, we describe a multiplex approach to evaluate selected
peptide epitopes of p53 protein and propose a novel approach to increase speciﬁcity and potentially sensitivity for
discrimination between healthy women and women with cancerous masses. Materials and Methods: Twenty-mer
overlapping peptide epitopes of p53, generated by mapping the complete p53 sequence, were evaluated in a
multiplex immunoassay for their detection of serum AAbs in patients with ovarian cancer, using Luminex technology.
AAbs to the selected peptides and to p53 full-length protein were then detected in a multiplex immunoassay evalu-
ating 359 sera from healthy women and 285 sera from patients with early- and late-stage ovarian cancer. CA-125
levels were measured in all p53 AAb-positive sera. Results: We considered the AAb results together to identify
sera where both the full-length protein and at least one selected peptide epitope were positive and chose cutoffs that
reduced false positives from these AAbs to 1 of 359 samples, improving speciﬁcity. Using this combined approach, we
could identify 7 AAb-positive patients who were negative for CA-125 (concentrations below 35 IU/mL); this represents
26% of the p53-positive patients in the total population. Conclusion: By detecting p53 AAbs in CA-125enegative
sera, we demonstrated that combining measurement of AAbs to the full-length p53 protein and one or more selected
epitopes can potentially improve sensitivity and speciﬁcity for ovarian cancer detection.
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Ovarian cancer is the leading cause of gynecologic cancer death
worldwide. Serum CA-125 levels, combined with imaging tech-
niques, are currently used for monitoring disease recurrence and
therapeutic response. CA-125 as a diagnosis marker has limited
speciﬁcity and sensitivity for ovarian cancer.1 Although many
additional biomarkers have been proposed for ovarian cancer, with
the emergence of new proteomic technologies,2 no marker has been
proven sensitive and speciﬁc enough for screening.
Previous studies have demonstrated that combining biomarkers
has the potential to improve speciﬁcity and sensitivity and increaseClinical Diagnostics Group, Bio-Rad Laboratories, Hercules, CA
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antibodies (AAbs) to tumor-associated antigens is a relatively new
strategy that has been proposed to support early detection with high
speciﬁcity.7,8 AAbs to p53 protein have been detected in sera of
patients with various carcinomas, including ovarian cancer,9-13
making p53 an attractive AAb biomarker for diagnosis of ovarian
cancer. It was shown that p53 AAbs can be detected up to 3.8 years
before diagnosis in a cohort of normal-risk women with colorectal
cancer,14 and p53 AAbs were studied for their high predictive
value in high-risk populations.15 p53 AAbs were also evaluated for
monitoring residual ovarian cancer and were found to be more
sensitive than CA-125.16 Previous investigators studied immuno-
dominant epitopes recognized by p53 antibodies10; earlier attempts
to develop an immunoassay with synthetic peptides corresponding
to these epitopes were unsuccessful because they led to a high level
of false-negative results.17
In this report, we have developed a multiplex bead-based
assay, using Luminex technology, for the detection of AAbsClinical Ovarian and Other Gynecologic Cancer Month 2015 - 1
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selected peptide epitopes. We describe the use of an algorithm
combining AAbs against both the protein and 1 or 2 peptides to
increase the speciﬁcity and sensitivity for discriminating between
healthy women and women with cancerous masses. To determine
whether the use of this algorithm could complement the CA-125
serum test by multiplexing the p53 markers from our study with
serum CA-125 measurements, we further evaluated p53 AAb-
positive samples in CA-125enegative population.
Materials and Methods
Patient Sera
Sera from healthy female blood donors (n ¼ 359, median age of
65 years) were obtained from Gulf Coast Regional Blood Center.
Sera from women with ovarian cancer (n ¼ 285, median age of
61 years) were obtained from various vendors including Bio-
reclamation (Westbury, NY), ProteoGenex (Culver City, CA),
Asterand (Detroit, MI), or Cureline (South San Francisco, CA).
Sera were collected after diagnosis but before any treatment. Cancer
sera were divided between early (stage I/II) and late (stage III/IV)
disease (FIGO stage 1, n ¼ 88; stage 2, n ¼ 106; stage 3, n ¼ 74;
stage 4, n ¼ 17). After collection, all sera were stored at 80C.
Demographics are summarized in Table 1.
Protein and Peptides
Full-length p53 recombinant protein was obtained from Gen-
Script (Piscataway, NJ). The p53 (361-393) 33-mer C-terminal
peptide (sequence GSRAHSSHLKSKKGQSTSRHKKLMFKTE-
GPDSD) was obtained from Biomer Technology (Pleasanton, CA).
Epitope mapping was done to select peptide epitopes and utilized
overlapping 20-mer peptides each offset by 7 residues encompassing
the entire canonical sequence of p53 protein consisting of
393 amino acid residues (30 peptides). All peptides were obtained
by Pepscreen synthesis (Sigma-Aldrich, St. Louis, MO) and wereTable 1 Distribution of Stage and Histology for Evaluated
Sample Set
Disease Group Histology Number of Patients
Early-stage (I/II) ovarian
cancer patient cases
Serous 42
Mucinous 15
Endometrioid 23
Clear cell 2
Other epithelial
(subtype unknown)
105
Others 8
Total 195
Late-stage (III/IV) ovarian
cancer patient cases
Serous 61
Mucinous 12
Endometrioid 8
Clear-cell 7
Others 2
Total 90
Healthy controls NA 359
Abbreviation: NA ¼ not applicable.
nical Ovarian and Other Gynecologic Cancer Month 2015evaluated in a multiplex assay for their binding to serum AAb as
detailed in the following. Immunogenicity of the peptides was
assessed by the number of ovarian cancer sera with elevated relative
ﬂuorescence intensity (RFI) values and comparing peptide signal to
protein signal. A selected p53 (40-59) 20-mer peptide (sequence
MDDLMLSPDDIEQWFTEDPG) was resynthesized by Biomer
Technology for the study to provide larger quantities of material of
higher purity (> 90%).
CA-125 Measurement and Multiplex p53 AAb Assay
All CA-125 values for patient samples were obtained using the
Food and Drug Administrationeapproved LOCI CA-125 II
method on the Dimension Vista 500 system (Siemens Healthcare
Diagnostics, Erlangen, Germany). AAb measurement was made
using a multiplexed bead-based immunoassay. p53 protein and
peptides were covalently coupled individually to dyed carboxylated
magnetic beads using carbodiimide chemistry, according to a
protocol described elsewhere.18 Patient samples were diluted 1:60
in a triethanolamine buffer with 3% BSA and 50 mL was mixed
with antigen-coated magnetic beads, followed by incubation for
60 minutes with continuous mixing. After washing off excess sera
3 times with phosphate buffered saline/0.1% Tween-20, the beads
were mixed with an antihuman IgG antibody, labeled with
phycoerythrin, and incubated for 30 minutes with continuous
mixing. After 3 more wash steps, the bead ﬂuorescence was read
using a Bio-Plex 200 reader and Bio-Plex Manager 6.0 software
(Bio-Rad, Hercules, CA). Fluorescence intensity data were ac-
quired with the following advanced settings: 200 beads/region,
50 mL sample size, and doublet discriminator gate values of 5000
to 25,000, and RFI values were typically between 10 and 27,000.
Cutoffs were determined using the 99.9th percentile RFI of
the healthy population for each analyte. Cutoffs for the analytes
in the algorithm described in this report were assigned manually
to obtain only one false-positive sample in the healthy popula-
tion (of 359 patient samples); this healthy sample was positive
for p53 protein and for one of the p53 peptides at the assigned
cutoffs.
Statistical Analysis
All statistical analyses and receiver operating characteristic (ROC)
curves for evaluation of analyte performance were performed using
JMP 10 software (SAS, Cary, NC).
Results
Peptide Selection for Multiplex Assay
A complete set of overlapping 20-mer peptides, spanning the
entire sequence of the p53 protein, was screened for immunoreac-
tivity using an epitope mapping approach against 116 sera from
healthy women and sera from 267 women with ovarian cancer.
Each 20-mer peptide was interrogated independently in the mul-
tiplex assay. Two 20-mer peptides (amino acids 40-59 and
209-228) showed detection of high numbers of AAbs. The p53
peptide (40-59), localized toward the N-terminus of the protein,
detected 33 of 267 AAbs, using a 99th percentile cutoff, consistent
with the full-length protein (data not shown); this peptide was
selected as a conﬁrmatory epitope for the whole protein for our
study. A 33-mer C-terminal peptide (361-393), which showed
Table 2 Means With 95% CI and Diagnostic Performance (AUC) for Measurement of AAb Levels to p53 Full-Length Protein and
Peptides in Sera Derived From 359 Healthy Women and 285 OVCA Patients
Autoantibody Analyte
Healthy Controls (n [ 359);
Mean RFI (95% CI)
OVCA Cases (n [ 285);
Mean RFI (95% CI)
P Value for Comparison of
the Population Means AUC
p53 protein 519 (331-708) 2272 (1567-2978) <.001 0.540
p53 (361-393) peptide 207 (31-383) 918 (466-1369) .002 0.611
p53 (40-59) peptide 30 (17-43) 875 (437-1314) <.001 0.673
All 3 markers e e e 0.663
Population means are given in RFI and were compared using a Student t test. AUCs were calculated from the receiver operating characteristic curves of individual and multiplexed AAb biomarkers.
Abbreviations: AAb ¼ autoantibody; AUC ¼ area under the curve; CI ¼ conﬁdence interval; OVCA ¼ ovarian cancer; RFI ¼ relative ﬂuorescence intensity.
Audrey Arjomandi et algood performance in preliminary studies (data not shown), was
selected as a second epitope for the study.
Biomarker Performance in a Traditional Multiplex Assay
and Using a New Algorithm
To evaluate selected biomarker performance, a total of 359 sera
from healthy women and 285 sera from patients with ovarian
cancer were tested in the multiplex bead-based assay described
previously.
The best discrimination of cases versus controls for detected
AAbs was achieved for p53 (40-59) peptide (mean RFI, 875 vs. 30,
Table 2), with a statistically signiﬁcant difference between the
means of the 2 populations (P < .001). Area under the curve was
determined from ROC curves for each AAb analyte and for the
combination of the 3 multiplexed AAb analytes. Combining the
3 AAb markers in a traditional multiplex assay did not help to in-
crease assay performance over one individual marker, with a com-
bined AUC of 0.663, similar to the AUC of the peptide (40-59;
Table 2). Individual analysis for each marker showed that anti-p53
AAbs were found in sera from 14 (5%), 5 (2%), and 21 (7%)
patients with ovarian cancer using the full-length protein, p53
(361-393) peptide, and p53 (40-59) peptide, respectively, at aTable 3 AAb Positivity in the Total Ovarian Cancer Population
and in CA-125enegative Ovarian Cancer Patient
Samples (< 35 IU/mL) Using Individual AAb Markers,
a Traditional Approach, and the Algorithm
Number of Positive
Results in Total
Population
(n [ 285)
Number of
CA-125enegative
Patients (Cutoff 35),
Out of p53-Positive
Results
AAb to p53 proteina 14 (5%) 2 Of 14 (14%)
AAb to p53 (361-393)
peptidea
5 (2%) 1 Of 5 (20%)
AAb to p53 (40-59)
peptidea
21 (7%) 2 Of 21 (10%)
All 3 markers multiplexed
(traditional approach;
99.4% speciﬁcity)b
21 (7%) 2 Of 21 (10%)
Algorithm (99.7%
speciﬁcity)c
27 (9%) 7 Of 27 (26%)
aThe 99.9th percentile was used as cutoff value, which gave 1 false positive of 359, ie, 99.7%
speciﬁcity.
bThe 99.9th percentile was used as cutoff value for each analyte in the multiplex.
cAlgorithm allowing 1 false-positive patient sample in the healthy population and identifying
positives when full-length protein and at least 1 epitope were positive at the selected cutoff.99.9th percentile cutoff for each analyte (Table 3). Using the 99.9th
percentile cutoff for each of the 3 AAb analyte in the multiplex
assay, 2 sera were positive in the healthy population, which corre-
sponded to an assay speciﬁcity of 99.4%.
To potentially increase the assay speciﬁcity and sensitivity, we
analyzed the data using a new algorithm. We observed that samples
with markedly elevated signals for the peptide AAbs consistently
showed a strong signal for the protein AAb as well, suggesting that
the peptides represented dominant epitopes. By deﬁning a positive
result to be when both an AAb to full-length protein and an AAb
to one or more peptide epitopes were obtained, we were able to use
a lower signal cutoff, as described in the Materials and Methods
section. Furthermore, the speciﬁcity increased because there was
only one healthy control sample where both p53 protein and
peptide AAbs were simultaneously observed. By reducing the
number of allowed AAb false positives from 2 to 1 and therefore
decreasing considerably the cutoffs for each analyte, we improved
speciﬁcity from 99.4% to 99.7% using this new algorithm. In the
total cancer population studied, 27 sera were AAb positive using the
algorithm, which corresponded to 9% of the population, compared
with 21 positive sera using the traditional approach (Table 3). Seven
of the 27 p53 AAb-positive patients were negative for CA-125 (at a
cutoff of 35 IU/mL); only 2 of these samples were AAb positive
using the traditional approach based on higher cutoffs (Table 3).
Discussion
Our goal was to determine whether p53 AAb biomarkers could
be combined with the CA-125 serum assay to add value to the test
by increasing speciﬁcity and sensitivity. For this purpose, levels of
CA-125 were measured in all p53 AAb-positive sera. An ovarian
cancer test requires high speciﬁcity; to obtain a 10% positive pre-
dictive value, it has been proposed that the speciﬁcity of a laboratory
test should be 99.7%, with a sensitivity of at least 80%.19
The study described in this report included sera from women
with different stages of ovarian cancer (I-IV). Our results conﬁrm
previous ﬁndings by other investigators that p53 AAbs do not
possess sufﬁcient diagnostic sensitivity to be used as the sole
screening test,14,20 showing AUC values between 0.50 and 0.70
from ROC curve analysis. Our data also suggest that multiplexing
p53 protein and peptide epitopes in a traditional approach does
not improve assay performance compared with the use of one in-
dividual biomarker.
In this study, we sought to identify peptide AAbs that would
increase the speciﬁcity of p53 AAb determination. We found an
epitope from the N-terminus of p53 protein (amino acids 40-59)Clinical Ovarian and Other Gynecologic Cancer Month 2015 - 3
New Algorithm for Ovarian Cancer Detection
4 - Cliwhich can discriminate between healthy and OVCA patient samples
with a similar pattern for AAb detection as the protein. Previous
epitope mapping studies also demonstrated the immunogenicity
of the N-terminal portion of the protein.10,11,17,21 We chose to
use this peptide epitope, together with the 33-mer epitope at the
C-terminus of the protein, in a multiplex assay in combination with
the full-length protein. We used an algorithm specifying that a
positive result was deﬁned by AAb to full-length p53 and at least
1 of the 2 AAbs to a p53 epitope, at the chosen cutoff. This al-
gorithm allowed the use of lower cutoffs at 99.7% speciﬁcity, which
resulted in a higher p53 positivity rate in the total population and
detection of more patients with ovarian cancer who were negative
for the CA-125 marker compared with a traditional approach at
99.4% speciﬁcity. The rationale of this approach was based on the
fact that a positive assay result was established to be concordant with
the clinical result when both the full-length protein and at least one
of its epitopes could be detected, using the peptide as a conﬁrmatory
marker. This method allowed avoiding some of the protein limi-
tations; it mainly reduced the number of false-positive samples in
the healthy population.
This study has some limitations. A larger study is needed to
verify, and modify if needed, these cutoffs and should include
CA-125 protein level measurement for all the samples in the study.
In the traditional multiplex format, at least 2000 healthy patients
would be needed to obtain 99.9% speciﬁcity for each marker. We
acknowledge that there is no “test” set in this study, and a separate
investigation should include “pedigreed” samples rather than sam-
ples of convenience. This study does not have impact on new
biomarker discovery but rather shows the importance of multi-
plexing biomarkers effectively.
In conclusion, the use of protein and peptide epitopes together
is a novel way to identify AAbs more speciﬁc for ovarian cancer
screening. Additional studies are required to conﬁrm these obser-
vations and to determine whether this approach could be useful
with other AAb targets and serum markers.
Clinical Practice Points
 Autoantibody (AAb) measurement to p53 protein for ovarian
cancer detection has previously been studied and has not been
shown to be successful as a sole screening test for speciﬁc AAb
detection. p53 AAb detection combined with measurement of
the known marker CA-125 is not sufﬁcient to achieve a good
screening test performance.
 Here, we report the use of a novel algorithm that can increase
speciﬁcity, and potentially sensitivity, of a screening test by
combining p53 protein and selected conﬁrmatory epitopes. We
used this new algorithm to detect more AAbs to p53 in sera of
patients with ovarian cancer (vs. control sera) than when we use a
traditional multiplex approach.
 We believe that this approach can be applied to other biomarkers
as well and make screening tests more efﬁcient.nical Ovarian and Other Gynecologic Cancer Month 2015Acknowledgments
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